5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells
- PMID: 20846024
- DOI: 10.1089/hum.2010.058
5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells
Abstract
Conditionally replicative adenoviruses (CRAds) are widely used for cancer biotherapy and show a significant growth-suppressing effect on many types of cancer. However, it was reported that breast cancer was highly resistant to the infection of traditionally used adenovirus of serotype 5 (Ad5)-based CRAds. Although partial substitution of the fiber protein of replication-deficient Ad5 with that of adenovirus of serotype 35 (Ad35) facilitated infection of breast cancer cells by adenoviral vectors, it is still unknown whether this modification can improve CRAds in their tumor-eliminating capacity. We generated a 5/35 fiber-modified CRAd with a p53 cDNA construct and investigated whether this alteration in fiber region can make CRAds suppress the growth of breast cancer more effectively. Our data reinforced the proposal that 5/35-modified fiber conferred higher adenovirus infectivity for breast cancer cells than natural Ad5 fiber. Interestingly, 5/35 fiber-modified CRAd replicated more efficiently in breast cancer cells than Ad5-based CRAd. We also found 5/35 fiber-modified CRAd mediated higher expression of p53 in breast cancer cells. In vitro, 5/35 fiber-modified CRAd eliminated breast cancer cells more efficiently. Growth of xenograft tumors in nude mice was also significantly retarded by 5/35 fiber-modified CRAd. The 5/35 fiber-modified CRAd suppressed the growth of breast cancer cells more effectively than Ad5-based CRAd, both in vitro and in vivo. Thus CRAd with 5/35 hybrid fiber may be a promising vector for breast cancer treatment.
Similar articles
-
Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.Int J Cancer. 2007 Feb 15;120(4):935-41. doi: 10.1002/ijc.22338. Int J Cancer. 2007. PMID: 17131341
-
A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.Cancer Res. 2007 Sep 15;67(18):8783-90. doi: 10.1158/0008-5472.CAN-07-0357. Cancer Res. 2007. PMID: 17875719
-
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.Gene Ther. 2007 Jan;14(1):58-67. doi: 10.1038/sj.gt.3302830. Epub 2006 Aug 10. Gene Ther. 2007. PMID: 16900223 Free PMC article.
-
A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.Cancer Biol Ther. 2017 Nov 2;18(11):833-840. doi: 10.1080/15384047.2017.1395115. Epub 2017 Nov 16. Cancer Biol Ther. 2017. PMID: 29144842 Free PMC article. Review.
-
Engineering regulatory elements for conditionally-replicative adeno-viruses.Curr Gene Ther. 2003 Aug;3(4):357-85. doi: 10.2174/1566523034578311. Curr Gene Ther. 2003. PMID: 12871022 Review.
Cited by
-
Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches.Pharmaceutics. 2022 Aug 29;14(9):1811. doi: 10.3390/pharmaceutics14091811. Pharmaceutics. 2022. PMID: 36145559 Free PMC article. Review.
-
Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia.Oncotarget. 2013 Jun;4(6):860-74. doi: 10.18632/oncotarget.1018. Oncotarget. 2013. PMID: 23765161 Free PMC article.
-
Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.J Biomed Sci. 2016 Jul 28;23(1):55. doi: 10.1186/s12929-016-0273-0. J Biomed Sci. 2016. PMID: 27465066 Free PMC article.
-
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9. Biomark Res. 2024. PMID: 39538363 Free PMC article. Review.
-
Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma.BMC Cancer. 2013 Mar 9;13:108. doi: 10.1186/1471-2407-13-108. BMC Cancer. 2013. PMID: 23496980 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous